The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of getting painfully high inflation under control without a recession.

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

Wall Street is poised for a modest rise following encouraging inflation data, which showed the U.S. personal consumption ...

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...

India's Alkem Laboratories on Friday denied claims that batches of its products, Pan-D and Clavam 625, are not of standard ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...